Berlim 25/20 association
Alternative Names: Berlim 25/20 association coated tabletLatest Information Update: 26 Feb 2024
At a glance
- Originator EMS
- Class Antihyperglycaemics; Antihyperlipidaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Dyslipidaemias; Type 2 diabetes mellitus
Most Recent Events
- 01 Dec 2023 Phase-III clinical trials in Dyslipidaemias (Treatment-experienced) in Brazil (PO) (NCT04602754)
- 01 Dec 2023 Phase-III clinical trials in Type 2 diabetes mellitus (Treatment-experienced) in Brazil (PO) (NCT04602754)
- 29 Oct 2020 EMS plans a phase III trial for Type 2 diabetes mellitus and Dyslipidemias (PO, Tablet) in December 2021 (NCT04602754)